KZR News and Press, Kezar Life Sciences Inc. From 02/26/24

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2...

2024-02-02 05:37:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In stock markets, uncovering penny stocks with a 10X boost potential is rare, but possible. This requires the identification of extraordinary growth potency. Among the multitude of stocks, thre...

2023-12-18 08:51:02 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the labyrinth of the stock market, discovering penny growth stocks often promises exhilarating prospects. This article navigates through the tumultuous waves of investment options, spotl...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore I...

2023-11-14 01:54:03 ET More on Kezar Life Sciences Kezar Life Sciences names new CEO, says to cut workforce by about 41% Seeking Alpha’s Quant Rating on Kezar Life Sciences Historical earnings data for Kezar Life Sciences Financial information for Keza...

Strategic restructuring extends cash runway to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis Collaboration and license agreement with Everest Medicines to develop and commercialize zetomipzomib in Greater China, South Korea and Southeast Asia ...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Kezar Life Sciences Inc. (KZR) is expected to report $-0.36 for Q3 2023

Strategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41% Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026 Co-Founder and Board Dire...

2023-09-24 22:33:00 ET Summary Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene...